August 2026 Research Update

Across these single-patient reports, a repeated pattern was that IgG4-related disease can look like cancer or other inflammatory conditions, especially when a mass or enlarged lymph nodes are present. The reports emphasize that diagnosis was strongest when doctors put together imaging results, blood IgG4 levels, and tissue examination, rather than relying on any one clue alone. They also show that IgG4-positive cells and high blood IgG4 are not always specific, so follow-up testing and sometimes repeat biopsy may be needed when the course does not fit. [1] [2] [3] [4] [5]

In one man with epigastric pain, MRI and magnetic resonance cholangiopancreatography (MRCP) showed classic pancreas and bile duct changes, and a very high blood IgG4 level supported autoimmune pancreatitis type 1 with IgG4-related cholangitis. The authors highlighted that using imaging together with blood testing helped confirm the diagnosis and reduce the risk of unnecessary surgery. [1]

In a woman with swelling of both tear glands and protrusion of the eyes, diagnosis depended on both a markedly elevated blood IgG4 level and tissue testing showing many IgG4-positive immune cells in the mass. The report shows how tissue confirmation can clarify the cause of a visible lump when imaging and symptoms alone cannot. [2]

In a man with a periureteral lesion and hydronephrosis that looked like upper urinary tract cancer, an intraoperative biopsy with frozen-section review found no cancer and final tissue testing supported IgG4-related disease. The authors described how a biopsy approach designed to safely identify the ureter helped avoid removing the kidney and ureter when the problem was inflammatory rather than malignant. [3]

Two reports focused on diagnostic pitfalls: one man was first labeled as having probable IgG4-related disease based on elevated blood IgG4 and IgG4-positive cells in a biopsy, but a later biopsy showed Hodgkin lymphoma. Another woman had liver and spleen involvement with high eosinophils and elevated blood IgG4 that initially resembled IgG4-related disease or lymphoma, but a lymph node biopsy showed non-caseating granulomas consistent with sarcoidosis after other causes were excluded. [4] [5]

For patients, these reports mainly serve as background on why diagnosis can take time and may involve more than one type of test, especially when symptoms involve a mass (for example near the pancreas, tear glands, ureter, liver, or lymph nodes). They reinforce that a high IgG4 blood test or IgG4-positive cells in tissue can be helpful but may not fully rule out other conditions like lymphoma or sarcoidosis. What remains uncertain is how often these specific pitfalls occur, because the evidence here comes from individual cases rather than larger studies.

Across these studies, several measurable markers (blood tests, a breath test, and immune-cell patterns) moved in the same direction as overall IgG4-related disease activity or risk of coming back. The evidence is mostly from single-center observational cohorts, so these tools look informative but not yet definitive for all patients or all organs. [6] [7] [8]

In a retrospective study of 77 people, very high blood IgG4 (at least 5 times the lab upper limit) was linked to more multi-organ involvement and more lymph node involvement than lower-IgG4 groups. That same very high IgG4 group also showed a pattern of higher total protein and globulin, lower albumin, and lower complement C3, suggesting a broader immune activation pattern when IgG4 is extremely elevated. [6]

In 35 people who had not yet received oral glucocorticoids, a non-invasive breath test (fractional exhaled nitric oxide) rose alongside higher blood IgG4, more organs involved, and higher disease activity scores. Higher breath-test values were also linked to lung involvement seen on computed tomography, with good ability to separate those with versus without lung involvement in this small study. [7]

In a prospective cohort of 74 adults followed through remission induction, relapse occurred in about one quarter during follow-up, and certain baseline immune features were more common in those who relapsed. Higher levels of a specific helper T-cell subset (Tph2 cells) and lower CD19+ B cells in blood were each linked to relapse risk, and a combined T-cell and B-cell pattern seen in lacrimal gland tissue (a T-B pathotype) also tracked with higher relapse risk; this tissue pattern was reproduced in a very small external set. [8]

For patients and caregivers, these papers suggest that tracking IgG4-related disease may eventually use more than one kind of marker: standard blood tests (IgG4 and related proteins/complement), a simple breath measurement that may be particularly relevant when lung involvement is a concern, and more specialized immune-cell testing aimed at estimating relapse risk. Right now, the breath and immune-cell approaches are based on relatively small, mostly single-center studies, and it is still uncertain how well they work across different hospitals, different organs, or after treatment has started. [6] [7] [8]

Across this group of papers, treatment discussions centered on two related goals: getting inflammation under control and reducing the chance of relapse. A 2026 expert review emphasized B cell-targeting antibodies as key treatment options, while a prospective cohort study focused on what happened after a first relapse and suggested some strategies were linked to fewer repeat relapses. Several single-patient reports illustrated how treatment choices played out in specific organ situations (eye socket, lungs) or in overlap with another immune disease, but these individual experiences may not apply to most people. [9] [10] [11] [12] [13]

A 2026 expert review, updating the 2015 international recommendations with newer studies, described rituximab or obinutuzumab (anti-CD20 antibodies) and inebilizumab (an anti-CD19 antibody) as first-line options for IgG4-related disease, and noted that rituximab had higher response rates with fewer side effects than prednisone in prior experience. The same review also highlighted relapse prevention, stating that early relapse after rituximab occurs in about 16-20% and that maintenance treatment is recommended to help prevent relapses. It also noted that combining rituximab with cyclophosphamide may extend how long responses last, while evidence for several other medicines mainly comes from case reports, small series, or phase II studies, with phase III results still awaited. [9]

In a prospective cohort of 259 people followed for at least 12 months after their first relapse, intensifying both glucocorticoids (steroids) and immunosuppressants was linked to fewer repeat relapses than intensifying immunosuppressants alone (hazard ratio 0.29). Steroids alone showed a trend toward fewer relapses than immunosuppressants alone, but this was not statistically clear in this study. The differences were more pronounced among people with internal organ involvement, and a decision-tree model suggested that an early drop in blood IgG4 and a reduction in a disease activity score were linked to staying relapse-free. [10]

Single-patient reports showed how relapse and organ involvement can affect treatment choices and follow-up. One 48-year-old man with an eye-socket mass and facial pain improved on corticosteroids but relapsed during tapering; after two courses of rituximab, imaging showed the mass had shrunk and pain improved over long-term follow-up. Another report described isolated lung disease that did not improve with antibiotics, where treatment with cyclosporine plus mycophenolate mofetil was followed by symptom improvement and smaller lung lesions on CT scans over 1 to 2 months. [11] [12]

One additional case report described overlap features between granulomatosis with polyangiitis (ANCA-associated vasculitis) and IgG4-related disease, including high blood IgG4 and noninvasive nasal and kidney masses. This patient achieved durable remission without ongoing glucocorticoids after treatment that included rituximab plus other immune-directed medicines, and the authors discussed the possibility that some overlap cases may respond to B cell-targeted therapy. Because this is one person with an overlap condition, it cannot show what will happen in typical IgG4-related disease. [13]

For patients and caregivers, these papers mainly add context about how relapse is being approached in 2026 and what kinds of treatments are being emphasized in expert recommendations. The strongest information here comes from a prospective follow-up study in people who had already relapsed once, plus an expert treatment review; the case reports help explain what relapse can look like in specific organs or in overlap with another immune disease, but they do not predict outcomes for most people. Important uncertainties remain, including the best long-term maintenance approach for preventing relapse and how well less-studied medicines compare in larger trials.

Across this topic, one observational cohort study suggests that watchful waiting in IgG4-related disease (IgG4-RD) can be safer for some people than others, with stability more common when there is no internal organ involvement. When progression happened, it tended to happen early rather than slowly over many years, and certain organ patterns and blood markers were linked to higher risk. [14]

In 40 people managed with watchful waiting, 12 progressed over follow-up, with fewer progression events among those without internal organ involvement (5 events) than among those with internal organ involvement (7 events). People without internal organ involvement had a higher probability of staying stable over time in this cohort. [14]

Timing also mattered: all progression events occurred within the first year, and the estimated risk of progression peaked around 6 to 8 months before declining. This pattern suggests that if progression occurs during watchful waiting, it may be more likely to show up earlier rather than later. [14]

Among people without internal organ involvement, progression was linked to paranasal sinus involvement, a higher disease activity score (response index), and higher eosinophil percentage and immunoglobulin E (IgE) levels in blood tests. These factors may help explain why some people progressed despite having no internal organ involvement at the time watchful waiting started. [14]

For patients and caregivers, this study mainly helps describe which situations looked more stable during watchful waiting and when changes were most likely to show up, rather than proving what the best approach is for everyone. The results are most relevant as near-term context (especially the first year) and as background for understanding why clinicians may pay closer attention to people with internal organ involvement, sinus involvement, or higher allergy-type blood markers. It remains uncertain how well these risk patterns apply to broader IgG4-RD populations because this was a single, small cohort and watchful waiting decisions may differ across centers. [14]

This month, the evidence came entirely from single-patient case reports, showing how IgG4-related disease can involve many different organs and sometimes look like other conditions at first. Several reports described mass-like or inflammatory changes in the pancreas and bile system, eye and nerve areas, thyroid and nearby throat structures, and even coronary (heart) arteries, with diagnosis supported by imaging, blood IgG4 levels, and/or tissue biopsy. Overall, these cases highlight that organ-specific symptoms can be the first clue, and that confirmation sometimes depended on getting tissue, while in other situations diagnosis was made clinically when biopsy was not possible. [15] [16] [17] [18] [19] [20] [21] [22] [23]

Digestive system presentations included autoimmune pancreatitis and bile-duct narrowing with jaundice or diarrhea, with imaging descriptions such as a "sausage-shaped" pancreas and thickened bile ducts. One person had diabetic ketoacidosis together with very high triglycerides during autoimmune pancreatitis, and improved after hospital stabilization plus early steroid treatment, but the report cannot prove cause and effect. [15] [16]

Two reports involved the gallbladder. One described two different inflammatory conditions in different parts of the gallbladder (IgG4-related sclerosing cholecystitis plus xanthogranulomatous cholecystitis), with a fistula to the colon arising from the non-IgG4 lesion. Another described difficult surgery for repeated gallbladder inflammation in a man taking prednisolone for IgG4-related disease; the report did not link the gallbladder inflammation to IgG4-related disease. A mucosal stripping approach was used as a bailout, with an uneventful recovery and no recurrence reported for more than two years. [17] [21]

Several reports focused on less common sites: coronary artery and aortic wall thickening suggesting IgG4-related cardiovascular disease, tissue around multiple cranial nerves that initially resembled orbital cellulitis, and an orbital mass extending into the skull causing eye bulging. In these cases, biopsy and imaging supported the diagnosis, and steroid treatment was followed by symptom and/or imaging improvement in the individual patients described. [18] [20] [22]

Rare structural complications were also reported, including probable Riedel's thyroiditis extending into the larynx with destruction of thyroid cartilage, and a very large bilateral paratesticular mass in an adult with Down syndrome that was initially suspected to be cancer but was diagnosed as IgG4-related disease after surgery and tissue testing. These single cases emphasize that IgG4-related disease can sometimes cause invasive-appearing lesions, and imaging alone may not reliably separate it from malignancy in some settings. [23] [19]

For patients and caregivers, these reports mainly serve as background about the range of organs IgG4-related disease can affect and why it can be mistaken for other problems such as infection, cancer, or other inflammatory diseases. Because each paper describes only one person, it is not possible to estimate how often these complications happen or predict who might experience them. What remains uncertain is how frequently these rare presentations occur across different patient groups, and which tests are most reliable in each organ system when biopsy is not available.

Across two exploratory tissue studies of salivary gland involvement in IgG4-related disease, inflammation and fibrosis appeared tightly linked inside the affected tissue. Patterns pointed to helper T cell and B cell activity occurring alongside macrophage and fibroblast programs, suggesting that local immune-fibrotic teamwork may shape how much scarring develops. These results describe tissue biology rather than symptoms, and they do not prove which cell type starts the process. [24] [25]

In a 49-sample study using bulk gene activity profiling, lesions with stronger Th2-like inflammation also showed stronger signals of germinal center helper T cells and B cells/plasmablasts, plus macrophage programs linked to fibrosis. Specific genes tied to chronic helper T cell states (such as PDCD1 and TOX) and plasmablast features (such as JCHAIN and PRDM1) were higher in the Th2-high group. Blood measures often connected to allergy, including serum IgG4 and IgE, did not differ clearly between Th2-high and Th2-low lesions in this dataset. [24]

In a very small spatial mapping study of two untreated patients, fibrosis-high regions contained an SPP1-centered niche where SPP1-expressing macrophages sat near collagen (COL1A1) and fibroblast-rich areas. The same regions showed higher signaling linked to PDGF and TGF-beta, which are pathways often discussed in scarring biology, and they also showed T cell states marked by exhaustion-related programs (including PDCD1 and TOX). The authors also described immune network shifts toward Tph-type helper T cells and more extrafollicular B cell activity, with less of a germinal center B cell pattern in the more fibrotic areas. [25]

For patients and caregivers, these studies mainly add background on what may be driving inflammation and scarring inside IgG4-related disease salivary gland lesions. They suggest that tissue-level immune activity (helper T cells, B cells/plasmablasts, and certain macrophages) may be more informative about fibrosis than general blood allergy markers, at least in these datasets. What remains uncertain is whether the same patterns hold in other organs, whether they predict future scarring in an individual person, and which interactions are causes versus byproducts of ongoing disease.

One exploratory study looked at IgG4-positive cells in lung biopsy samples from people with rheumatoid arthritis (not IgG4-related disease) who had abnormal chest CT scans. A small subgroup met an IgG4-rich definition in the lung tissue and also tended to show a distinct immune-cell pattern in bronchoalveolar lavage (a lung wash). The results suggest IgG4-rich lung infiltration may sometimes appear in the setting of smoking-related lung injury and rheumatoid arthritis-related immune activity, but the study cannot show cause and effect. [26]

Out of 28 rheumatoid arthritis patients, six were classified as IgG4-rich in lung tissue using an IgG4/IgG ratio threshold of 10%. All six were male ever-smokers, had higher anti-CCP antibody (ACPA) levels, and had lower baseline breathing test values (percent FEV1.0). The tissue IgG4/IgG ratio rose with higher ACPA and was higher in people with lower percent FEV1.0 (poorer lung function). [26]

Compared with the IgG4-low group, the IgG4-rich group had bronchoalveolar lavage fluid with a lower CD4/CD8 ratio, higher CD8 cells, and higher CD22-positive B cells, while the blood immune profile did not show clear differences. Chest CT patterns also differed, with more interstitial lung disease and higher emphysema scores reported in the IgG4-rich group. The authors noted important limitations, including small sample size, an exploratory cutoff, and difficulty separating the effects of smoking from sex. [26]

This study is most relevant as context for how IgG4-positive cells can show up in lung tissue outside IgG4-related disease, particularly in people with rheumatoid arthritis and smoking-related lung changes. It does not establish that these patients had IgG4-related disease, and it does not clarify whether IgG4-positive cells are driving lung damage or are part of a broader immune reaction to injury. Larger studies with clearer definitions and confirmation of the cell types involved are needed before this kind of tissue signal can be interpreted confidently.